News

2008 consolidated turnover: +134%

Strong sales growth A pro-active partnering strategy BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced a 2008 turnover of €8.2 million, strongly increased from €3.5 million in 2007. Over the course of 2008, the company pro-actively pursued its international licensing and partnering strategy, notably via…read more →

BioAlliance Pharma presents results on a new quinoline family on HIV integrase inhibitors at the 16th Conference on Retroviruses and Opportunistic Infections (CROI)

Paris, February 6, 2009 – BioAlliance Pharma SA (Euronext Paris-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announces the presentation of its results on a new quinoline family acting as HIV integrase inhibitors at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), in Montreal, Canada (February 8 to 11, 2009). The…read more →

BioAlliance Pharma publishes its 2009 financial calendar

Paris, January 15, 2009 – BioAlliance Pharma SA (Euronext Paris – ticker code BIO) has announced its financial calendar for 2009, which notably includes the publication dates for its revenue statements and half-year & annual accounts, as well as the date of its shareholders’ Annual General Meeting: February 11, 2009 Publication of the revenue statement for Q4 2008 and of…read more →